- Home
- SGHT vs ADCT Comparison
SGHT vs ADCT Comparison
Compare SGHT & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- ADCT
- Stock Information
- Founded
- SGHT 2011
- ADCT 2011
- Country
- SGHT United States
- ADCT Switzerland
- Employees
- SGHT N/A
- ADCT N/A
- Industry
- SGHT Medical Specialities
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- SGHT Health Care
- ADCT Health Care
- Exchange
- SGHT Nasdaq
- ADCT Nasdaq
- Market Cap
- SGHT 140.1M
- ADCT 127.9M
- IPO Year
- SGHT 2021
- ADCT 2020
- Fundamental
- Price
- SGHT $3.03
- ADCT $1.28
- Analyst Decision
- SGHT Buy
- ADCT Strong Buy
- Analyst Count
- SGHT 7
- ADCT 5
- Target Price
- SGHT $3.92
- ADCT $7.75
- AVG Volume (30 Days)
- SGHT 161.2K
- ADCT 235.3K
- Earning Date
- SGHT 05-08-2025
- ADCT 05-14-2025
- Dividend Yield
- SGHT N/A
- ADCT N/A
- EPS Growth
- SGHT N/A
- ADCT N/A
- EPS
- SGHT N/A
- ADCT N/A
- Revenue
- SGHT $78,109,000.00
- ADCT $70,837,000.00
- Revenue This Year
- SGHT N/A
- ADCT $6.82
- Revenue Next Year
- SGHT $11.17
- ADCT $18.56
- P/E Ratio
- SGHT N/A
- ADCT N/A
- Revenue Growth
- SGHT N/A
- ADCT 1.84
- 52 Week Low
- SGHT $2.03
- ADCT $1.05
- 52 Week High
- SGHT $8.45
- ADCT $4.83
- Technical
- Relative Strength Index (RSI)
- SGHT 56.13
- ADCT 43.00
- Support Level
- SGHT $2.81
- ADCT $1.23
- Resistance Level
- SGHT $3.26
- ADCT $1.49
- Average True Range (ATR)
- SGHT 0.24
- ADCT 0.08
- MACD
- SGHT -0.01
- ADCT 0.00
- Stochastic Oscillator
- SGHT 38.57
- ADCT 25.00
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).